This technology allows to overcome the gastric barrier for protein compounds, administering bioactive molecules (insulin, heparin, antigens, hormones, etc) with the advantage of being a controlled release (delayed release mechanism). This finding can be used for other non-protein compounds and other drugs. 1.2. In particular, this technology has been experimented on rats and other diabetizados animals to replace daily and repeated doses of injectable insulin, a product of oral administration. Also, the process has experienced in research with other protein and non-protein compounds.

(1.3 Process is characterized by the following steps: to) first production of a mixture of at least one appropriate monomer for polymerization by ionizing radiation, with at least one aqueous solution of bioactive molecules or other drugs. b) place the mixture thus obtained in a container resistant, permeable to ionizing radiation and the presentation of said container to a flow of ionizing radiation at doses able to polymerize the monomer, in a range of 0.1 to 50 kGy kGy, from this process of obtained a polymer resistant to stomach acid and specific features of the retard release. You can configure the settings for the solution, specific radiation doses, determine the size, shape and physical characteristics of nanotubes formed in polymer. It also determines the speed of release of bioactive compounds or drugs included. Polymer, usually a Hydrogel, and the active substance (nanotubes) inside with little or no hydration, swallowed and reaches the stomach, where suffers no alteration, or structural degradation, or changes, as well nor release of significant amounts of active substance. Simplifying, this development offers a product that decreases the number (for example, in the case of diabetics who need insulin) daily and repeated injections of the drug, through the intake of a pill taken by mouth. Steps 1.4 corresponding to this innovation patent. Information can be viewed on the web at the following site: world of intellectual property (WIPO) in the field of patents (PCT) 1.5 discussion until today, we have developed a model of polymers including controlled insulin release; that by the relevance of the topic, media availability, and the help of expert clinicians has been obtained surprising results in experimental animals.